However, uncertainties in the management of HER2+ breast cancer patients remain, such as the optimal chemotherapy regimen that should be administered with trastuzumab and the length of trastuzumab therapy, although the empiric 1-year duration is the standard of care. This evidence concerns the gene ERBB2 and breast carcinoma.